Richard young 2023

Richard Young

Managing Director and Principal Toxicologist

UKRT/ERT

Richard has >20 years’ experience in desk-based toxicology at bibra. He has an MSc in Applied Toxicology and is a RSB/BTS and European Registered Toxicologist (ERT). His skills include expert analysis of human health data. This can involve the pragmatic application of risk assessment methodology to mammalian toxicity data sets in order to derive robust conclusions on toxicological acceptability and health risks to exposed populations. In 2018, Richard became the Managing Director of bibra.

Richard has worked for clients from the food and beverage, food contact materials, consumer goods, agrochemical, biocidal, industrial chemical, pharmaceutical, electronic cigarette and cannabinoid sectors. For the past 15 years, he has been heavily involved in assisting companies comply with their REACH registration obligations, including supporting registrants respond to ECHA Evaluation decisions. Richard has played a key role in assisting e-cigarette and e-liquid manufacturers and importers with the toxicological assessments of their products, notably with their EU TPD and US FDA PMTA compliance obligations. Most recently he has been involved in the toxicological assessment of cannabinoids (notably CBD and THC) for a number of clients from a range of sectors (e.g. food, consumer products and pharmaceuticals).

In his spare time Richard can be found playing padel tennis and 5-a-side football (when his knees can cope), and running around and entertaining his two children.

Richard's case studies and blog posts

Hazard characterisation of several e-liquid ingredients

Case study

The client is required to provide regulatory authorities with up-to-date toxicological information related to the ingredients used in their products. Bibra were provided with a list of several substances and asked to produce a hazard review (considering the requirements of the European Tobacco Products Directive, TPD2) for each.

Cannabinoids – preparation of several inhalation focused toxicity profiles

Case study

The client requested the production of a series of urgent toxicity profiles for more than a dozen different cannabinoids, to support and inform their Research & Development (R&D) of new inhalable (non nicotine) consumer products (including their possible incorporation as ingredients into e liquids).

FDA memoranda: genotoxicity and carcinogenicity assessments of ENDS

Blog articles

As discussed in a previous blog post, the U.S. Food and Drug Administration (FDA) Center for Tobacco Products (CTP) has issued several “scientific policy memoranda” that provide some great insights into the Agency’s evaluation process. In June 2024, the FDA made two new memos available that relate to the genotoxicity and carcinogenicity assessment of chemical constituents of Electronic Nicotine Delivery Systems (ENDS).

Want to read more case studies and blog posts that Richard has been involved in? Click below to read more.

Contact us